Avenue Therapeutics (ATXI) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 13, 2024
Document Information [Line Items]
Entity Central Index Key	0001644963
Entity Registrant Name	AVENUE THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-38114
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4113275
Entity Address, Address Line One	1111 Kane Concourse, Suite 301
Entity Address, City or Town	Bay Harbor Islands
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33154
City Area Code	781
Local Phone Number	652‑4500
Title of 12(b) Security	Common Stock
Trading Symbol	ATXI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		940,986

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,194	$ 1,783
Prepaid expenses and other current assets	116	67
Total assets	3,310	1,850
Current Liabilities:
Warrant liability	413	586
Total current liabilities	1,412	1,196
Total liabilities	1,412	1,196
Commitments and contingencies
Stockholders’ equity (deficit)
Preferred stock ($0.0001 par value), 2,000,000 shares authorized Class A Preferred stock, 250,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common shares, 590,188 and 341,324 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	3
Additional paid-in capital	98,104	92,507
Accumulated deficit	(95,268)	(90,928)
Total stockholders’ equity attributed to the Company	2,836	1,582
Non-controlling interests	(938)	(928)
Total stockholders’ equity	1,898	654
Total liabilities and stockholders’ equity	3,310	1,850
Nonrelated Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	647	287
Related Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	$ 352	$ 323

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred Stock, shares issued (in shares)	250,000	250,000
Preferred Stock, shares outstanding (in shares)	250,000	250,000
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized (in shares)	200,000,000	75,000,000
Common Stock, shares issued (in shares)	590,188	341,324
Common Stock, shares outstanding 1 (in shares)	590,188	341,324

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,392	$ 1,215
Research and development – licenses acquired	0	4,230
General and administrative	1,316	984
Loss from operations	(3,708)	(6,429)
Other income (expense):
Interest income	49	37
Financing costs – warrant liabilities	0	(332)
Loss on settlement of common stock warrant liabilities	(574)	0
Change in fair value of warrant liabilities	(116)	(878)
Total other income (expense)	(641)	(1,173)
Net loss	(4,349)	(7,602)
Net loss attributable to non-controlling interests	(9)	(66)
Net loss attributable to common stockholders	$ (4,340)	$ (7,536)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (15.4)	$ (101.57)
Weighted average number of common shares outstanding, basic and diluted (in shares)	562,031	74,198

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Preferred Stock [Member] Preferred Class A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022	250,000	63,671
Balance at Dec. 31, 2022	$ 0	$ 0	$ 84,456	$ (80,551)	$ (639)	$ 3,266
Share based compensation (in shares)	0	0
Share based compensation	$ 0	$ 0	11	0	0	11
Issuance of common stock to Fortress (in shares)	0	4,997
Issuance of common stock to Fortress	$ 0	$ 0	72	0	0	72
Exercise of warrants (in shares)	0	5,335
Exercise of warrants	$ 0	$ 0	0	0	0	0
Net loss attributable to non-controlling interests	0	0	0	0	(66)	(66)
Net loss attributable to common stockholders	$ 0	$ 0	0	(7,536)	0	(7,536)
Balance (in shares) at Mar. 31, 2023	250,000	91,066
Balance at Mar. 31, 2023	$ 0	$ 0	86,635	(88,087)	(705)	(2,157)
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement (in shares)	0	5,974
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement	$ 0	$ 0	865	0	0	865
Issuance of common stock for license acquisition (in shares)	0	11,089
Issuance of common stock for license acquisition	$ 0	$ 0	1,231	0	0	1,231
Balance (in shares) at Dec. 31, 2023	250,000	341,324
Balance at Dec. 31, 2023	$ 0	$ 3	92,507	(90,928)	(928)	654
Share based compensation (in shares)	0	283
Share based compensation	$ 0	$ 0	191	0	0	191
Common shares issuable - Founders Agreement	$ 0	$ 0	(363)	0	0	(363)
Issuance of common stock to Fortress (in shares)	0	28,019
Issuance of common stock to Fortress	$ 0	$ 0	371	0	0	371
Loss on settlement of common stock warrant liabilities	$ 0	$ 0	574	0	0	574
Exercise of warrants (in shares)	0	220,538
Exercise of warrants	$ 0	$ 1	5,261	0	0	5,262
Warrant inducement offering costs	$ 0	$ 0	(442)	0	0	(442)
Reverse split (1-for-75) (in shares)		24
Reverse split (1-for-75)		$ (4)	4	0	0	0
Non-controlling interest in subsidiaries	0	0	1	0	(1)	0
Net loss attributable to non-controlling interests	0	0	0	0	(9)	(9)
Net loss attributable to common stockholders	$ 0	$ 0	0	(4,340)	0	(4,340)
Balance (in shares) at Mar. 31, 2024	250,000	590,188
Balance at Mar. 31, 2024	$ 0	$ 0	$ 98,104	$ (95,268)	$ (938)	$ 1,898

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Parentheticals)	3 Months Ended
	Mar. 31, 2024
Reverse Stock Split [Member]
Stock Split, Conversion Ratio	75

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (4,349)	$ (7,602)
Reconciliation of net loss to net cash used in operating activities:
Share based compensation	191	11
Loss on settlement of common stock warrant liabilities	574	0
Change in fair value of warrant liabilities	116	878
Issuance of Stock for Licenses Acquired	0	1,230
Common Stock, Issued to Fortress, Value	371	72
Issuance of Stock Under Founders Agreement	(363)	0
Changes in operating assets and liabilities:
Other receivables - related party	0	(13)
Prepaid expenses and other current assets	(49)	(61)
Accrued licenses acquired	0	3,000
Net cash used in operating activities	(3,120)	(1,573)
Cash flows from financing activities:
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement	0	3,101
Exercise of warrants	4,973	0
Warrant transaction costs	(442)	0
Net cash provided by financing activities	4,531	3,101
Net change in cash and cash equivalents	1,411	1,528
Cash and cash equivalents, beginning of period	1,783	6,708
Cash and cash equivalents, end of period	3,194	8,236
Supplemental cash flow information:
Unpaid research and development licenses acquired	0	3,000
Issuance of common shares - Founders Agreement	371	0
Related Party [Member]
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	360	889
Nonrelated Party [Member]
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	$ 29	$ 23

Note 1 - Organization, Plan of

Note 1 - Organization, Plan of Business Operations	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 - Organization, Plan of Business Operations Avenue Therapeutics, Inc. (the “Company” or “Avenue”) was incorporated in Delaware on February 9, 2015, AJ201 101 Authorized Share Increase On January 9, 2024, February 20, 2024, Reverse Stock Split On April 25, 2024, 1 one April 26, 2024, April 26, 2024. No one one All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Going Concern These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, as described below, substantial doubt about the Company’s ability to continue as a going concern exists. The Company is not may March 31, 2024 1b/2a AJ201, 3 12 one not may

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with U.S. GAAP, include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented and are stated in U.S. dollars. The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiary. All intercompany balances and transactions have been eliminated. The accompanying unaudited interim condensed financial statements include the accounts of the Company's subsidiary, Baergic. Because the Company owns less than 100% may Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not December 31, 2023, 10 “2023 10 March 18, 2024. Segments Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one operating and reportable segment. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Fair Value Measurements The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third Net Loss per Share Net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Net loss attributable to common stockholders consisted of net loss, as adjusted for deemed dividends. The Company recorded a deemed dividend of $4.3 million for the modification of certain of its existing warrants and issuance of warrants during the three March 31, 2024 ( 7 8 The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not For the Three Months Ended March 31, 2024 2023 Unvested restricted stock units/awards 1,028 177 Warrants 745,139 95,607 Options 22,474 — Class A Preferred shares 223 223 Total potential dilutive effect 768,864 96,007 Summary of Significant Accounting Policies There have been no 2023 10

Note 3 - License Supplier Agree

Note 3 - License Supplier Agreement	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
License Agreement Disclosure [Text Block]	Note 3 Licenses/Supplier Agreements IV Tramadol License Effective as of February 17, 2015, June 17, 2015, December 2019, On October 29, 2018, eight five Baergic Licenses In December 2019, two 2 3 α2,3 Development milestones totaling approximately $81.5 million in the aggregate are due upon achievement of each milestone. Commercial and sales-based milestone payments totaling approximately $151 million are due upon achievement of each milestone, as well as royalty payments in the low to high single digits on any future aggregate, annual, worldwide net sales. AnnJi License Agreement On February 28, 2023, AJ201. AJ201 April 27, 2023 September 8, 2023. 1b/2a first The license provided under the AnnJi License Agreement is exclusive as to all oral forms of AJ201 AJ201 AJ201 In connection with the signing of the AnnJi License Agreement, the Company issued 11,089 shares of its common stock to AnnJi (“First Tranche Shares”) at a fair value of $0.9 million on March 30, 2023. September 26, 2023 eighth 1b/2a February 28, 2023, In connection with execution of the AnnJi License Agreement, Avenue entered into a registration rights agreement with AnnJi, pursuant to which Avenue filed a registration statement to register the resale of the First Tranche Shares and Second Tranche Shares issued to AnnJi. The Company filed such registration statement on Form S- 3 June 16, 2023, June 27, 2023.

Note 4 - Related Party Agreemen

Note 4 - Related Party Agreements	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 4 Related Party Agreements Founders Agreement and Management Services Agreement with Fortress In February 2015, three March 31, 2024 2023, In February 2015, two one two one three March 31, 2024 2023, three March 31, 2024. Pursuant to the Third Amended and Restated Certificate of Incorporation, the Company issued 22,476 shares of common stock to Fortress for the Annual Equity Fee during the three March 31, 2024. December 31, 2023. three March 31, 2023, December 31, 2022. Founders Agreement and Management Services Agreement with Baergic Pursuant to the Share Contribution Agreement between Avenue and Fortress, the Founders Agreement and Management Services Agreement that had previously been existing between Fortress and Baergic were assigned to Avenue, such that they now exist between Avenue and Baergic; those agreements are referred to herein as the Avenue-Baergic Founders Agreement and the Avenue-Baergic MSA, as applicable. The Annual Stock Dividend payable to the Company is 2.5% of common stock calculated as a percentage of fully diluted outstanding capital and became effective as of November 8, 2022. The Avenue-Baergic Founders Agreement has an effective date of March 9, 2017, 15 one As additional consideration under the Avenue-Baergic Founders Agreement, Baergic will also: (i) pay an equity fee in shares of common stock, payable within five 5 no two one four one ninety 90 one five 5x twelve 12 four one The Avenue-Baergic MSA has an effective date of March 9, 2017, five five may not not no first

Note 5 - Accounts Payable and A

Note 5 - Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 5 Accounts Payable and Accrued Expenses Accounts payable, accrued expenses, and other liabilities consisted of the following (in thousands): As of March 31, As of December 31, 2024 2023 Accounts payable $ 310 $ 78 Accrued employee compensation 94 11 Accrued contracted services and other 243 198 Total accounts payable and accrued expenses $ 647 $ 287

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6 - Commitments and Contingencies Leases The Company is not Litigation The Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can be reasonably estimated. When a range of probable loss can be estimated, the Company will accrue the most likely amount of such loss, and if such amount is not March 31, 2024, no

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Equity [Text Block]	Note 7 Class A Preferred Stock On September 13, 2016, may one not On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number of votes that is equal to one one tenth 1.1 Each share of Class A Preferred Stock is convertible, at the option of the holder, into one not one September 2022 April 2024, one Common Stock On January 9, 2024, February 20, 2024, Holders of the Company's common stock are entitled to one not may In the event of the Company's liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no may may Capital Raises 2021 On December 7, 2021, No. 333 261520 3, December 10, 2021 ( 2021 March 31, 2024. January 2024 On January 5, 2024, “January 2023 “January 2023 January 2023 January 31, 2023 ( “January 2023 “November 2023 January 2023 “January 2024 “November 2023 January 2023 November 2023 November 2, 2023 ( “November 2023 January 2023 January 2023 November 2023 Pursuant to the January 2024 January 2023 January 2023 November 2023 November 2023 x five eighteen The January 2023 January 5, 2024 8 January 2023 November 2023 January 2023 November 2023 2 The Company received aggregate net proceeds of approximately $4.5 million from the exercise of the Existing Warrants by the Holders, after deducting placement agent fees and other expenses payable by the Company. The Company filed a registration statement on Form S- 3 No. 333 276671 January 24, 2024, February 1, 2024. The key inputs for the Black-Scholes Model calculations on January 5, 2024 January 2023 New Series A New Series B Warrants Warrants Warrants Stock price $ 14.25 $ 14.25 $ 14.25 Risk-free interest rate 4.40 % 4.02 % 4.40 % Expected dividend yield — — — Expected term in years 2.1 5.0 1.5 Expected volatility 185 % 138 % 187 % Equity Incentive Plan The Company has in effect the Avenue Therapeutics, Inc. 2015 “2015 2015 January 2015 December 2021. 2015 January 30, 2023. 2015 no Total shares available for the issuance of stock-based awards under the Company’s 2015 March 31, 2024 Restricted Stock Units and Restricted Stock Awards The following table summarizes the restricted stock unit and award activity during the three March 31, 2024 Number of Weighted Units and Average Grant Awards Date Fair Value (in thousands) Unvested balance at December 31, 2023 1,311 $ 196.21 Granted — — Forfeited — — Vested (283 ) 85.50 Unvested balance at March 31, 2024 1,028 $ 226.69 At March 31, 2024 not March 31, 2024 Stock Options The following table summarizes stock option activity during the three March 31, 2024 Weighted Average Number Weighted Remaining Aggregate of Options Average Contractual Intrinsic Value (in thousands) Exercise Price Term (years) (in thousands) Outstanding at December 31, 2023 22,474 $ 85.50 9.5 $ — Granted — $ — $ — Exercised — $ — $ — Cancelled/forfeited — $ — $ — Expired — $ — $ — Outstanding at Balance at March 31, 2024 22,474 $ 85.50 9.2 $ — Expected to vest 16,304 $ 85.50 9.2 $ — Exercisable 6,170 $ 85.50 9.2 $ — There were no options granted in the three March 31, 2024. March 31, 2024 not The Company did not three March 31, 2024 2023. Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations as follows: For the three months ended March 31, March 31, 2024 2023 Research and development $ 45 $ — General and administrative 146 11 Total stock-based compensation expense $ 191 $ 11 Stock Warrants The following table summarizes the warrant activity for the three March 31, 2024 2023 Weighted Average Aggregate Exercise Intrinsic Value Warrants Price (in thousands) Outstanding, December 31, 2023 524,601 $ 32.42 $ — Granted 441,076 22.55 Exercised (220,538 ) 22.55 Outstanding, March 31, 2024 745,139 $ 29.50 $ — Upon the exercise of warrants, the Company will issue new shares of its common stock. InvaGen Share Repurchase Under the Share Repurchase Agreement, the Company agreed to pay InvaGen an additional amount as a contingent fee, payable in the form of seven January 2024 January 2024, May 2024 9 May 2024.

Note 8 - Common Stock Warrant L

Note 8 - Common Stock Warrant Liabilities	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Common Stock Warrant Liabilities [Text Block]	Note 8 The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 815. 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Warrant Liability The Company has previously issued freestanding warrants to purchase shares of its common stock in connection with financing activities. The outstanding October 2022 January 2023 The fair value of the warrants was measured at the time of issuance and is re-measured at each financial reporting date with any changes in fair value being recognized in change in fair value of warrant liabilities, a component of other income (expense), in the consolidated statements of operations and comprehensive income (loss). The Company will continue to re-measure the fair value of the October 2022 October 10, 2027. In January 2024, January 2023 January 2023 January 2023 January 5, 2024, 7 Fair Value of Warrant Liabilities Warrant liabilities are categorized within Level 3 October 2022 January 2023 Warrants Warrants Total Fair value of warrants outstanding as of December 31, 2023 $ 426 $ 160 $ 586 Change in fair value of warrants (13 ) 129 116 Exercise of warrants — (289 ) (289 ) Fair value of warrants outstanding as of March 31, 2024 $ 413 $ — $ 413 The key inputs for the October 2022 March 31, December 31, 2024 2023 Stock price $ 11.10 $ 12.00 Risk-free interest rate 4.21 % 3.84 % Expected dividend yield — — Expected term in years 3.5 3.8 Expected volatility 162 % 148 %

Note 9 - Subsequent Events

Note 9 - Subsequent Events	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9 - Subsequent Events Reverse Stock Split On April 25, 2024, one not not No no April 26, 2024, April 26, 2024. not May 2024 On April 28, 2024, “May 2024 “October 2022 October 2022 “November 2023 November 2023 “January 2024 October 2022 November 2023 October 2022 November 2023 October 2022 November 2023 May 2024 x “May 2024 “May 2024 May 2024 May 2024 May 1, 2024 ( At-the-Market Facility In May 2024, may May 10, 2024 ( 424 1933, Under current SEC regulations and General Instruction I.B.6 3, $75.0 $75.0 12 one third March 31, 2024, $75.0 As a result of the warrant inducement transaction, and as of the date of this filing, the Company believes it has stockholders’ equity of at least $2.5 5550 1

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. During the three March 31, 2024, none 16a 1 10b5 1 10b5 1 408 1933
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with U.S. GAAP, include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented and are stated in U.S. dollars. The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiary. All intercompany balances and transactions have been eliminated. The accompanying unaudited interim condensed financial statements include the accounts of the Company's subsidiary, Baergic. Because the Company owns less than 100% may Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not December 31, 2023, 10 “2023 10 March 18, 2024.
Segment Reporting, Policy [Policy Text Block]	Segments Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one operating and reportable segment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not
Noncontrolling Interests [Policy Text Block]	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Net loss attributable to common stockholders consisted of net loss, as adjusted for deemed dividends. The Company recorded a deemed dividend of $4.3 million for the modification of certain of its existing warrants and issuance of warrants during the three March 31, 2024 ( 7 8 The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not For the Three Months Ended March 31, 2024 2023 Unvested restricted stock units/awards 1,028 177 Warrants 745,139 95,607 Options 22,474 — Class A Preferred shares 223 223 Total potential dilutive effect 768,864 96,007

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	For the Three Months Ended March 31, 2024 2023 Unvested restricted stock units/awards 1,028 177 Warrants 745,139 95,607 Options 22,474 — Class A Preferred shares 223 223 Total potential dilutive effect 768,864 96,007

Note 5 - Accounts Payable and_2

Note 5 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	As of March 31, As of December 31, 2024 2023 Accounts payable $ 310 $ 78 Accrued employee compensation 94 11 Accrued contracted services and other 243 198 Total accounts payable and accrued expenses $ 647 $ 287

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 31, December 31, 2024 2023 Stock price $ 11.10 $ 12.00 Risk-free interest rate 4.21 % 3.84 % Expected dividend yield — — Expected term in years 3.5 3.8 Expected volatility 162 % 148 %
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]	Number of Weighted Units and Average Grant Awards Date Fair Value (in thousands) Unvested balance at December 31, 2023 1,311 $ 196.21 Granted — — Forfeited — — Vested (283 ) 85.50 Unvested balance at March 31, 2024 1,028 $ 226.69
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Number Weighted Remaining Aggregate of Options Average Contractual Intrinsic Value (in thousands) Exercise Price Term (years) (in thousands) Outstanding at December 31, 2023 22,474 $ 85.50 9.5 $ — Granted — $ — $ — Exercised — $ — $ — Cancelled/forfeited — $ — $ — Expired — $ — $ — Outstanding at Balance at March 31, 2024 22,474 $ 85.50 9.2 $ — Expected to vest 16,304 $ 85.50 9.2 $ — Exercisable 6,170 $ 85.50 9.2 $ —
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	For the three months ended March 31, March 31, 2024 2023 Research and development $ 45 $ — General and administrative 146 11 Total stock-based compensation expense $ 191 $ 11
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Average Aggregate Exercise Intrinsic Value Warrants Price (in thousands) Outstanding, December 31, 2023 524,601 $ 32.42 $ — Granted 441,076 22.55 Exercised (220,538 ) 22.55 Outstanding, March 31, 2024 745,139 $ 29.50 $ —
Warrant [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	January 2023 New Series A New Series B Warrants Warrants Warrants Stock price $ 14.25 $ 14.25 $ 14.25 Risk-free interest rate 4.40 % 4.02 % 4.40 % Expected dividend yield — — — Expected term in years 2.1 5.0 1.5 Expected volatility 185 % 138 % 187 %

Note 8 - Common Stock Warrant_2

Note 8 - Common Stock Warrant Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	October 2022 January 2023 Warrants Warrants Total Fair value of warrants outstanding as of December 31, 2023 $ 426 $ 160 $ 586 Change in fair value of warrants (13 ) 129 116 Exercise of warrants — (289 ) (289 ) Fair value of warrants outstanding as of March 31, 2024 $ 413 $ — $ 413
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 31, December 31, 2024 2023 Stock price $ 11.10 $ 12.00 Risk-free interest rate 4.21 % 3.84 % Expected dividend yield — — Expected term in years 3.5 3.8 Expected volatility 162 % 148 %

Note 1 - Organization, Plan o_2

Note 1 - Organization, Plan of Business Operations (Details Textual) $ / shares in Units, $ in Thousands		3 Months Ended
	Apr. 25, 2024	Mar. 31, 2024 USD ($) $ / shares shares	May 31, 2024 $ / shares	Jan. 09, 2024 $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares) | shares		200,000,000		200,000,000	75,000,000
Retained Earnings (Accumulated Deficit) | $		$ (95,268)			$ (90,928)
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		75
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	75

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Number of Reportable Segments	1
Deemed Dividends	$ 4.3
Number of Operating Segments	1

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive securities (in shares)	768,864	96,007
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	1,028	177
Warrant [Member]
Antidilutive securities (in shares)	745,139	95,607
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	22,474	0
Class A Preferred Shares [Member]
Antidilutive securities (in shares)	223	223

Note 3 - License Supplier Agr_2

Note 3 - License Supplier Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended	4 Months Ended
	Sep. 26, 2023	Apr. 27, 2023	Mar. 30, 2023	Feb. 28, 2023	Oct. 29, 2018	Dec. 31, 2019	Mar. 31, 2023	Jun. 17, 2015
Contractual Obligation Development Expense						$ 81,500
Contractual Obligation, Commercial Expense						$ 151,000
Stock Issued During Period, Value, License Expense							$ 1,231
AnnJi [Member]
License Agreement, Purchase Consideration				$ 3,000
Payments to Acquire License		$ 2,000
Acquired License Payable Within 180 Days				1,000
Maximum Reimbursement Amount In Connection With Product Clinical Trial				10,800
Maximum Reimbursement Amount In Connection With Certain Development Milestones				14,500
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone				27,500
Maximum Reimbursement Amount Upon Achievement of Sales Milestone				165,000
Stock Issued During Period, Shares, License Expense (in shares)			11,089
Stock Issued During Period, Value, License Expense			$ 900
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares)	3,688
Stock Issuable During Period, Value, Upon Enrollment of Patient	$ 300
AnnJi [Member] | Minimum [Member]
Sales Milestone Required for Maximum Reimbursement				75,000
Annual Sale Threshold for Royalty Payment				50,000
AnnJi [Member] | Maximum [Member]
Sales Milestone Required for Maximum Reimbursement				750,000
Annual Sale Threshold for Royalty Payment				$ 300,000
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments								$ 3,000
Baergic Licenses [Member] | CCHMC [Member]
Percentage of Equity Fee						5%
Polpharma [Member]
Payments to Acquire in Process Research and Development					$ 2,000
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Upfront Payment [Member]
Payments to Acquire in Process Research and Development								2,000
Percentage of Equity Fee						20%
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member]
Payments to Acquire in Process Research and Development						$ 1,000		$ 1,000
Baergic Licenses [Member] | Upfront Payment [Member] | CCHMC [Member]
Payments to Acquire in Process Research and Development						200
Baergic Licenses [Member] | Upfront Payment [Member] | AZERBAIJAN
Payments to Acquire in Process Research and Development						$ 3,000
AnnJi [Member]
Right to Sell Common Stock, Price Per Share (in dollars per share)	$ 2.1

Note 4 - Related Party Agreem_2

Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 09, 2017	Feb. 28, 2015	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2022
Research and Development Expense			$ 2,392	$ 1,215
Fortress [Member]
Percentage of Fully-diluted Outstanding Equity		2.50%
Percentage of Equity or Debt Fnancing		2.50%
Stock Issued During Period, Shares, New Issues (in shares)			5,543	1,912
Stock Issuable During Period, Shares, Financing Equity Fee (in shares)			5,513
Stock Issued During Period, Shares, Annual Equity Fee (in shares)			22,476	3,085
Fortress [Member] | Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000
Fortress [Member] | Annual Equity Fees [Member]
Research and Development Expense					$ 300	$ 300
Fortress [Member] | Management Services Agreement [Member]
Costs and Expenses			$ 100	$ 100
Fortress [Member] | Research and Development Expense [Member] | Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50%
Fortress [Member] | General and Administrative Expense [Member] | Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50%
BaergicBio, Inc.[Member] | Avenue Baergic Founders Agreement [Member]
Percentage of Equity Fee							2.50%
Percentage Of Additional Consideration Of Equity Fee						2.50%
Percentage Considered For The Calculation Of One-Time Fee						4.50%
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500
Increase in Annual Consulting Fee	$ 1,000

Note 5 - Accounts Payable and_3

Note 5 - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - Nonrelated Party [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts payable	$ 310	$ 78
Accrued employee compensation	94	11
Accrued contracted services and other	243	198
Total accounts payable and accrued expenses	$ 647	$ 287

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands

3 Months Ended

Jan. 05, 2024 USD ($) $ / shares shares

Feb. 03, 2023 USD ($)

Jan. 30, 2023 shares

Mar. 31, 2024 USD ($) $ / shares shares

Mar. 31, 2023 USD ($) shares

Jan. 31, 2024 $ / shares shares

Jan. 09, 2024 shares

Dec. 31, 2023 $ / shares shares

Nov. 30, 2023 $ / shares shares

Jan. 31, 2023 $ / shares shares

Sep. 22, 2022

Dec. 31, 2021 shares

Sep. 13, 2019 $ / shares

Sep. 13, 2016 shares

Preferred Stock, Shares Authorized (in shares)

2,000,000

2,000,000

2,000,000

Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Common Stock, Shares Authorized (in shares)

200,000,000

200,000,000

75,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 29.5

$ 32.42

Fair Value Adjustment of Warrants | $

$ 116

$ 878

Proceeds from Warrant Exercises | $

$ 4,973

$ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)

283

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

0

0

Invagen Pharmaceuticals Inc [Member]

Contingent Fee, Percentage of Proceeds of Future Financings

7.50%

Contingent Fee, Maximum Allowable Amount | $

$ 4,000

Restricted Stock Units (RSUs) [Member]

Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $

$ 100

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)

1 year 4 months 24 days

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)

45

Share-Based Payment Arrangement, Option [Member]

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)

1 year 7 months 6 days

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $

$ 700

Two Thousand Fifteen Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)

70,223

3,556

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)

10 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)

44,701

January 2023 Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

25,871

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 22.545

$ 116.25

Fair Value Adjustment of Warrants | $

$ 100

November 2023 Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

194,667

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 22.545

$ 22.545

New Series A Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

220,538

Warrants and Rights Outstanding, Term (Year)

5 years

Warrants and Rights Issued Classified as Deemed Dividend | $

$ 600

New Series B Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

220,538

Warrants and Rights Issued Classified as Deemed Dividend | $

$ 4,300

Existing Warrants [Member]

Proceeds from Warrant Exercises | $

$ 4,500

January 2024 Warrant Inducement [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

25,871

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 22.545

January 2024 Warrant Inducement [Member] | Invagen Pharmaceuticals Inc [Member]

Payment of Contingent Fee | $

$ 300

May 2024 Warrant Inducement [Member] | Invagen Pharmaceuticals Inc [Member]

Payment of Contingent Fee | $

300

Shelf [Member]

Securities, Remaining Available for Sale, Amount | $

$ 24,900

Preferred Class A [Member]

Preferred Stock, Shares Authorized (in shares)

250,000

Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

Preferred Stock, Convertible, Conversion Ratio

1,125

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Schedule of Warrants under the Black-Scholes Model (Details)	Jan. 05, 2024
Measurement Input, Share Price [Member] | January 2023 Warrants [Member]
Warrant Liability	14.25
Measurement Input, Share Price [Member] | New Series A Warrants [Member]
Warrant Liability	14.25
Measurement Input, Share Price [Member] | New Series B Warrants [Member]
Warrant Liability	14.25
Measurement Input, Risk Free Interest Rate [Member] | January 2023 Warrants [Member]
Warrant Liability	0.044
Measurement Input, Risk Free Interest Rate [Member] | New Series A Warrants [Member]
Warrant Liability	0.0402
Measurement Input, Risk Free Interest Rate [Member] | New Series B Warrants [Member]
Warrant Liability	0.044
Measurement Input, Expected Dividend Rate [Member] | January 2023 Warrants [Member]
Warrant Liability	0
Measurement Input, Expected Dividend Rate [Member] | New Series A Warrants [Member]
Warrant Liability	0
Measurement Input, Expected Dividend Rate [Member] | New Series B Warrants [Member]
Warrant Liability	0
Measurement Input, Expected Term [Member] | January 2023 Warrants [Member]
Warrant Liability	2.1
Measurement Input, Expected Term [Member] | New Series A Warrants [Member]
Warrant Liability	5
Measurement Input, Expected Term [Member] | New Series B Warrants [Member]
Warrant Liability	1.5
Measurement Input, Price Volatility [Member] | January 2023 Warrants [Member]
Warrant Liability	1.85
Measurement Input, Price Volatility [Member] | New Series A Warrants [Member]
Warrant Liability	1.38
Measurement Input, Price Volatility [Member] | New Series B Warrants [Member]
Warrant Liability	1.87

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Restricted Stock Unit and Award Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Unvested balance (in shares) | shares	1,311
Unvested balance, Weighted average grant date fair value (in dollars per share) | $ / shares	$ 196.21
Granted (in shares) | shares	0
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Forfeited (in shares) | shares	0
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Vested (in shares) | shares	(283)
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	$ 85.5
Unvested balance (in shares) | shares	1,028
Unvested balance, Weighted average grant date fair value (in dollars per share) | $ / shares	$ 226.69

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Outstanding, options (in shares)	22,474
Outstanding, weighted average exercise price (in dollars per share)	$ 85.5
Outstanding, aggregate intrinsic value			$ 0
Granted, options (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)	$ 0
Exercised, options (in shares)	0
Exercised, weighted average exercise price (in dollars per share)	$ 0
Cancelled/forfeited, options (in shares)	0
Cancelled/forfeited, weighted average exercise price (in dollars per share)	$ 0
Expired, options (in shares)	0
Expired, weighted average exercise price (in dollars per share)	$ 0
Outstanding, options (in shares)	22,474
Outstanding, weighted average exercise price (in dollars per share)	$ 85.5
Outstanding, remaining term (Year)	9 years 2 months 12 days
Expected to vest, options (in shares)	16,304
Expected to vest, weighted average exercise price (in dollars per share)	$ 85.5
Expected to vest, remaining term (Year)	9 years 2 months 12 days
Expected to vest, aggregate intrinsic value	$ 0
Exercisable, options (in shares)	6,170
Exercisable, weighted average exercise price (in dollars per share)	$ 85.5
Exercisable, remaining term (Year)	9 years 2 months 12 days
Exercisable, aggregate intrinsic value	$ 0

Note 7 - Stockholders' Equity-

Note 7 - Stockholders' Equity- Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation	$ 191	$ 11
Research and Development Expense [Member]
Stock-based compensation	45	0
General and Administrative Expense [Member]
Stock-based compensation	$ 146	$ 11

Note 7 - Stockholders' Equity_5

Note 7 - Stockholders' Equity- Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Warrants, outstanding (in shares)	524,601
Outstanding, weighted average exercise price (in dollars per share)	$ 32.42
Outstanding, December 31, 2023	$ 0	$ 0
Warrants, Granted (in shares)	441,076
Warrants granted, weighted average exercise price (in dollars per share)	$ 22.55
Warrants, Exercised (in shares)	(220,538)
Exercised, weighted average exercise price (in dollars per share)	$ 22.55
Warrants, outstanding (in shares)	745,139	524,601
Outstanding, weighted average exercise price (in dollars per share)	$ 29.5	$ 32.42

Note 8 - Common Stock Warrant_3

Note 8 - Common Stock Warrant Liabilities (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Jan. 05, 2024	Mar. 31, 2024	Mar. 31, 2023	Jan. 31, 2024	Dec. 31, 2023	Jan. 31, 2023
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 29.5			$ 32.42
Fair Value Adjustment of Warrants		$ 116	$ 878
January 2024 Warrant Inducement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 22.545
January 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 22.545					$ 116.25
Warrants and Rights Outstanding	$ 300
Fair Value Adjustment of Warrants	$ 100

Note 8 - Common Stock Warrant_4

Note 8 - Common Stock Warrant Liabilities - Fair Value of Warrants Liabilities Measured Within Level 3 on Recurring Basis (Details) - Warrant [Member] - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Fair value of warrants outstanding	$ 586
Change in fair value of warrants	116
Exercise of warrants	(289)
Fair value of warrants outstanding	413
October 2022 Warrants [Member]
Fair value of warrants outstanding	426
Change in fair value of warrants	(13)
Exercise of warrants	0
Fair value of warrants outstanding	413
January 2023 Warrants [Member]
Fair value of warrants outstanding	160
Change in fair value of warrants	129
Exercise of warrants	(289)
Fair value of warrants outstanding	$ 0

Note 8 - Common Stock Warrant_5

Note 8 - Common Stock Warrant Liabilities - Schedule of Warrants under Monte Carlo Simulation and Black-Scholes Model (Details) - October 2022 Warrants [Member]	Mar. 31, 2024	Dec. 31, 2023
Measurement Input, Share Price [Member]
Warrant Liability	11.1	12
Measurement Input, Risk Free Interest Rate [Member]
Warrant Liability	0.0421	0.0384
Measurement Input, Expected Dividend Rate [Member]
Warrant Liability	0	0
Measurement Input, Expected Term [Member]
Warrant Liability	3.5	3.8
Measurement Input, Price Volatility [Member]
Warrant Liability	1.62	1.48

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual)				3 Months Ended
	Apr. 28, 2024 USD ($) $ / shares shares	Apr. 25, 2024	Jan. 05, 2024 USD ($) $ / shares	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 USD ($)	May 31, 2024 USD ($) $ / shares	Jan. 09, 2024 $ / shares	Dec. 31, 2023 $ / shares	Nov. 30, 2023 $ / shares shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 29.5				$ 32.42
Proceeds from Warrant Exercises | $				$ 4,973,000	$ 0
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001			$ 0.0001	$ 0.0001
November 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares									194,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 22.545						$ 22.545
Existing Warrants [Member]
Proceeds from Warrant Exercises | $			$ 4,500,000
Subsequent Event [Member]
Offering Agreement, Maximum Amount | $						$ 3,850,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001
Subsequent Event [Member] | October 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	27,271
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 116.25
Subsequent Event [Member] | November 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	221,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 22.545
Subsequent Event [Member] | New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	441,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 22.545
Subsequent Event [Member] | Existing Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.2
Proceeds from Warrant Exercises | $	$ 4,400,000
Subsequent Event [Member] | New Class C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	689,680
Subsequent Event [Member] | New Class D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	689,680
Subsequent Event [Member] | May 2024 Warrant Inducement [Member]
Warrant Payment, Price Per Share (in dollars per share)	$ 0.125
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				75
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		75